Abstract:Therapeutic antibodies must have "drug-like" properties. These include high affinity and specificity for the intended target, biological activity, and additional characteristics now known as "developability properties": long-term stability and resistance to aggregation when in solution, thermodynamic stability to prevent unfolding, high expression yields to facilitate manufacturing, low self-interaction, among others. Sequence-based liabilities may affect one or more of these characteristics. Improving the stability and developability of a lead antibody is typically achieved by modifying its sequence, a time-consuming process that often results in reduced affinity. Here we present a new antibody library format that yields high-affinity binders with drug-like developability properties directly from initial selections, reducing the need for further engineering or affinity maturation. The innovative semi-synthetic design involves grafting natural complementarity-determining regions (CDRs) from human antibodies into scaffolds based on well-behaved clinical antibodies. HCDR3s were amplified directly from B cells, while the remaining CDRs, from which all sequence liabilities had been purged, were replicated from a large next-generation sequencing dataset. By combining two in vitro display techniques, phage and yeast display, we were able to routinely recover a large number of unique, highly developable antibodies against clinically relevant targets with affinities in the subnanomolar to low nanomolar range. We anticipate that the designs and approaches presented here will accelerate the drug development process by reducing the failure rate of leads due to poor antibody affinities and developability.Abbreviations: AC-SINS: affinity-capture self-interaction nanoparticle spectroscopy; CDR: complementarity-determining region; CQA: critical quality attribute; ELISA: enzyme-linked immunoassay; FACS: fluorescence-activated cell sorting; Fv: fragment variable; GM-CSF: granulocyte-macrophage colony-stimulating factor; HCDR3: heavy chain CDR3; IFN2a: interferon α-2; IL6: interleukin-6; MACS: magnetic-activated cell sorting; NGS: next generation sequencing; PCR: polymerase chain reaction; SEC: size-exclusion chromatography; SPR: surface plasmon resonance; TGFβ-R2: transforming growth factor β-R2; VH: variable heavy; VK: variable kappa; VL: variable light; Vl: variable lambda.

De Novo Synthesis and Structural Elucidation of CDR-H3 Loop Mimics

De Novo Synthesis and Structural Elucidation of CDR-H3 Loop Mimics

CDR-H3 loop ensemble in solution – conformational selection upon antibody binding

Antibody CDR loops as ensembles in solution vs. canonical clusters from X-ray structures

Transitions of CDR-L3 Loop Canonical Cluster Conformations on the Micro-to-Millisecond Timescale

Do antibody CDR loops change conformation upon binding?

The role of CDR H3 in antibody recognition of a synthetic analog of a lipopolysaccharide antigen.

Comparative Analysis of the CDR Loops of Antigen Receptors

Antibody humanization—the Influence of the antibody framework on the CDR-H3 loop ensemble in solution

Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues.

50 years of antibody numbering schemes: a statistical and structural evaluation reveals key differences and limitations

Drug-like antibodies with high affinity, diversity and developability directly from next-generation antibody libraries

Atomically accurate de novo design of single-domain antibodies

CDR L3 Loop Rearrangement Switches Multispecific SPE‐7 IgE Antibody From Hapten to Protein Binding

Rational design of CXCR4 specific antibodies with elongated CDRs.

Simple End-to-end Deep Learning Model for CDR-H3 Loop Structure Prediction

Accurate prediction of CDR-H3 loop structures of antibodies with deep learning

Structural Mimicry of CD4 by a Cross-reactive HIV-1 Neutralizing Antibody with CDR-H2 and H3 Containing Unique Motifs

Molecular Modeling and Affinity Determination of Scfv Antibody: Proper Linker Peptide Enhances Its Activity

Identification of Conformational Core Epitope Lys(68) in C5a Based on the 3-D Modeling Complex C5a and Its Functional Antibody F20

Experimental Structures of Antibody/MHC-I Complexes Reveal Details of Epitopes Overlooked by Computational Prediction